Pre-pregnancy and early clinical analysis of TORCH infections detection.
- Author:
Ai-Hua FU
1
Author Information
- Publication Type:Journal Article
- MeSH: Antibodies, Protozoan; blood; immunology; Antibodies, Viral; blood; immunology; Antiprotozoal Agents; therapeutic use; Antiviral Agents; therapeutic use; Cytomegalovirus; immunology; isolation & purification; Female; Humans; Immunoglobulin M; blood; immunology; Pregnancy; Pregnancy Complications, Infectious; drug therapy; immunology; parasitology; virology; Rubella virus; drug effects; immunology; isolation & purification; Simplexvirus; drug effects; immunology; isolation & purification; Toxoplasma; drug effects; immunology; isolation & purification; Treatment Outcome
- From: Chinese Journal of Experimental and Clinical Virology 2009;23(4):307-308
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVEFor the birth, to improve the quality of the population, to explore the prevention and treatment of early pregnancy TORCH infection, and treatment of patients with positive eugenics and guidance.
METHODSEnzyme-linked immunosorbent assay (ELISA) testing of all the objects in the peripheral blood-money pathogen-specific antibodies LgM. Person in charge of testing. In strict accordance with the instructions. Reagents from Shanghai magnolia biotechnology institute.
RESULTThe total number of 319 cases of positive, with a total infection rate: 3.28%, TOX-IgM, RV-IgM, CMV-IgM, HSV (II)-IgM infection rate of 0.103 percent, 2.64 percent and 0.309 percent, 0.237 percent; 319 cases of TORCH infected persons are to receive treatment for the treatment of wrap, with a total negative rate of 97.49 percent.
CONCLUSIONDetection of TORCH infections to ensure early diagnosis, early treatment and early prevention is necessary.
